Suppr超能文献

对庆大霉素对耐甲氧西林金黄色葡萄球菌、甲氧西林敏感金黄色葡萄球菌和万古霉素中介金黄色葡萄球菌临床分离株的活性评估。

Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates.

作者信息

Truelson Katherine A, Brennan-Krohn Thea, Smith Kenneth P, Kirby James E

机构信息

Boston University, Boston, MA, USA.

Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

出版信息

Diagn Microbiol Infect Dis. 2018 Oct;92(2):168-171. doi: 10.1016/j.diagmicrobio.2018.05.018. Epub 2018 May 29.

Abstract

We evaluated the in vitro activity of apramycin against clinical strains of vancomycin-intermediate and methicillin-resistant and -susceptible Staphylococcus aureus. Apramycin demonstrated an MIC/MIC of 8/16 μg/mL. No strains had an MIC above the epidemiological cutoff value of 32 μg/mL, suggesting apramycin resistance mechanisms are rare in this strain population. The mounting evidence for broad-spectrum in vitro activity of apramycin against S. aureus and other bacterial species suggests that further exploration of apramycin or derivatives as repurposed human therapeutics is warranted.

摘要

我们评估了阿普拉霉素对万古霉素中介型、耐甲氧西林和甲氧西林敏感的金黄色葡萄球菌临床菌株的体外活性。阿普拉霉素的最低抑菌浓度/最低杀菌浓度为8/16μg/mL。没有菌株的最低抑菌浓度高于32μg/mL的流行病学临界值,这表明在该菌株群体中阿普拉霉素耐药机制很少见。越来越多的证据表明阿普拉霉素对金黄色葡萄球菌和其他细菌具有广谱体外活性,这表明有必要进一步探索将阿普拉霉素或其衍生物用作重新利用的人类治疗药物。

相似文献

引用本文的文献

本文引用的文献

9
In vivo efficacy of apramycin in murine infection models.阿普拉霉素在小鼠感染模型中的体内疗效。
Antimicrob Agents Chemother. 2014 Nov;58(11):6938-41. doi: 10.1128/AAC.03239-14. Epub 2014 Aug 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验